Anzeige
Mehr »
Mittwoch, 09.07.2025 - Börsentäglich über 12.000 News
Schwergewicht aus London investiert Millionen in australisches Goldprojekt - was Anleger jetzt wissen müssen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CH7 | ISIN: GB00B2Q6HZ92 | Ticker-Symbol: 7EE
Stuttgart
09.07.25 | 10:04
0,022 Euro
0,00 % 0,000
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
DXS INTERNATIONAL PLC Chart 1 Jahr
5-Tage-Chart
DXS INTERNATIONAL PLC 5-Tage-Chart
GlobeNewswire (Europe)
60 Leser
Artikel bewerten:
(0)

DXS International PLC: Company Update

DXS INTERNATIONAL PLC (AQSE: DXSP)

ExpertCare selected for prestigious Grow Digital Health Midlands Programme

DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that ExpertCare, its digital medicine solution, has been selected for the prestigious Grow Digital Health Midlands Programme.

Grow Digital Health Midlands - a new collaboration from Health Innovation East Midlands and Health Innovation West Midlands, has announced its first cohort of nine high-potential digital health companies of which DXS and the ExpertCare solution is one. The programme is designed to help UK technology innovators scale proven solutions across the NHS and wider care system.

Following a competitive process receiving 51 applications, nine have been successful and will receive a tailored package of support, including:

  • Access to subject matter experts to aid product development; and
  • Significant opportunities to showcase DXS's innovations to NHS and care system decision-makers and influencers.

Gaining exposure to the largest NHS England region, encompassing 11 Integrated Care Systems and a population of approximately 11.8 million people, Grow Digital Health Midlands provides a platform to bring forward digital innovation that can address the NHS's most pressing challenges. The key themes for the cohort were to seek innovators who have solutions that enhance NHS productivity and communication and can reduce the demand for hospital based care.

Tim Robinson, Health Innovation East Midlands Commercial Director, said: "We're proud to welcome the nine exciting innovators to our Grow Digital Health Midlands programme.

This programme has been shaped by input from NHS and care leaders across the Midlands and is aligned with the government's national priorities, including the government's three shifts.* It was paramount that the companies demonstrated this as part of their application, demonstrating relevance and technology readiness.

We're excited to support their innovator journeys, and their growth to bring change to our health and care systems."

* The 10 Year Health Plan is set to outline three significant shifts that the government wants to make in health and care - from an analogue system to a digital one, from care in hospitals to care in the community, and from a system that treats sickness to one that prevents ill health.

The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts:

David Immelman
DXS International plc
www.dxs-systems.com


01252 719800
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.


© 2025 GlobeNewswire (Europe)
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.